Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Capecitabine
Xeloda
Routinely available
Local application
29/03/2023
Indication
First choice treatment for Dukes B colorectal cancer
Therapeutic Area
Malignant disease and immunosuppression
Status Description
Routinely available
Formulation
capecitabine/oxaliplatin (Xeloda/Eloxatin)
Comments
-